Floatz logo

Anti-Meso-Car Vector Transduced T Cells

Triple Negative Breast Cancer

Chinese PLA General HospitalCell therapyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

448 Active assets in the Triple Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Meso-Car Vector Transduced T Cells is also rated in:

malignant mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
ovarian neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
mesothelial neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →